Replies to post #21469 on RespireRx Pharmaceuticals Inc (fka RSPI)

[jerrydylan]

You folks want to see a wake....see CEGE, who once had $1 billion worth of Abgenix....or ...MEMY. That is what a wake looks like, both companies have deals but no efficasy.

[atheroprevent]

Jerry. that MRK layoff is on top of 10,000 already laid off this year.

Meanwhile the FDA delays 4 more drugs and there are rumors of additional delays in LLY's prasugrel which has already been delayed 9 months (they have a 1100 foot long box of data for FDA review with prasugrel 10,000+ patient study).

http://blogs.wsj.com/health/2008/10/22/in-two-days-four-new-drugs-stall-at-fda/?mod=yahoo_hs

It is understandable that BP is cautious before committing funds, given the resistance to new therapy by the FDA. BP's seems to be contracting with the rapid conversion to generic product driven by PBM's and tapped out patients (50% drop in MRK Fosamax sales this year).

All that said, I want to agree with Neuro's take, that given RD POC, BP cannot afford to overlook COR. We need competing interest to get favorable valuation forward.